Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Seaway Pharma Inc.
WARNING LETTER
•Seaway Pharma Inc.•June 18, 2025

Seaway Pharma Inc. – FDA Warning Letter, Jun 18, 2025

Record Details

The FDA issued a Warning Letter to Seaway Pharma Inc. following an inspection of their drug manufacturing facility in Massena, NY, from May 19 to June 18, 2025. The letter details significant violations of Current Good Manufacturing Practice (CGMP) regulations (21 CFR parts 210 and 211), rendering their drug products, particularly over-the-counter oral liquid medications for infants and children, adulterated.

Key issues identified include inadequate oversight by the Quality Control Unit (QU). The company failed to establish and follow written procedures, releasing numerous batches of drug products between April 2024 and May 2025 without fully reviewing all test results, including active ingredient strength and microbial testing, to ensure they met specifications. The FDA found the QU lacked sufficient resources and proper quality system controls.

Furthermore, Seaway Pharma Inc. failed to adequately test incoming drug components for identity, especially high-risk materials like glycerin and sorbitol solution, prior to their use in manufacturing. This is critical due to the potential for lethal diethylene glycol (DEG) or ethylene glycol (EG) contamination, despite the company"s assertion of no enforceable provisions (which the FDA refuted, citing USP standards enforceable under the FD&C Act).

Required actions include a comprehensive assessment and remediation plan for the QU to ensure its authority, resources, and robust oversight of all operations, including complete batch and component test result reviews before release. The company must also implement a rigorous program for testing all incoming components for identity, strength, quality, and purity, specifically including DEG/EG analysis for high-risk materials, and provide a commitment to ongoing quality unit review and approval.

Company
Seaway Pharma Inc.
Inspection date
June 18, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 9b5afeb8-99bf-42a5-8163-7cd92e201cf0

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.22(d)21 CFR 211.165(a)21 CFR 211.194(a)21 CFR 211.84(d)(1)FD&C Act 501(b)21 U.S.C. 351(b)

Full citation text and observation details available on the Dashboard.

Other documents for Seaway Pharma Inc.
  • 483 - 2025-06-18June 18, 2025
  • 483 - 2024-07-24July 24, 2024
  • 483 - 2023-09-21September 21, 2023
  • 483 - 2021-09-15September 15, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Seaway Pharma Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.